KWR:NYSEQuaker Houghton Analysis
Data as of 2026-05-25 - not real-time
$141.84
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Quaker Chemical is trading well above its discounted cash‑flow estimate, reflecting an **extremely high price‑to‑earnings ratio** that signals overvaluation. The company posted solid revenue growth of roughly eight percent year‑over‑year, yet profit margins remain razor‑thin, with earnings per share barely above breakeven. Operating cash flow is positive, and the dividend payout ratio is unusually low, suggesting the **current dividend is sustainable** despite the weak profitability. Technicals show a neutral price trend, a bearish MACD signal and decreasing volume, placing the stock near its recent support level while still below the identified resistance. Volatility is elevated at over forty percent on a 30‑day basis and beta exceeds 1.3, indicating the stock moves more aggressively than the market. Analyst consensus leans heavily bullish, but the earnings surprise was slightly negative, highlighting a disconnect between expectations and recent performance.
The balance sheet carries a high debt load relative to equity, and return on equity is near zero, raising concerns about long‑term capital efficiency. The forward price‑to‑earnings multiple has collapsed to a more reasonable level, yet the current market price remains far above the DCF fair value, implying limited upside. Sector dynamics for specialty chemicals are mixed, with growth opportunities offset by margin pressure and regulatory scrutiny. Given the combination of overvaluation, high volatility, and modest earnings quality, the stock appears better suited for a cautious stance rather than aggressive buying. Investors should monitor margin trends, debt reduction progress, and any shifts in the technical momentum before adjusting exposure.
The balance sheet carries a high debt load relative to equity, and return on equity is near zero, raising concerns about long‑term capital efficiency. The forward price‑to‑earnings multiple has collapsed to a more reasonable level, yet the current market price remains far above the DCF fair value, implying limited upside. Sector dynamics for specialty chemicals are mixed, with growth opportunities offset by margin pressure and regulatory scrutiny. Given the combination of overvaluation, high volatility, and modest earnings quality, the stock appears better suited for a cautious stance rather than aggressive buying. Investors should monitor margin trends, debt reduction progress, and any shifts in the technical momentum before adjusting exposure.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Bearish MACD histogram
- Decreasing volume trend
- Price near recent support
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- Revenue growth outpacing margin expansion
- Low dividend payout ratio supporting cash flow
- High debt-to-equity ratio limiting flexibility
Long Term
> 3 yearsCautious
Model confidence: 8/10
Key Factors
- Current price far above DCF fair value
- Extremely high trailing PE ratio
- Near‑zero ROE and elevated volatility
Key Metrics & Analysis
Financial Health
Revenue Growth8.50%
Profit Margin0.22%
P/E Ratio545.5
ROE0.32%
ROA4.34%
Debt/Equity65.95
P/B Ratio1.8
Op. Cash Flow$143.3M
Free Cash Flow$108.4M
Technical Analysis
TrendNeutral
RSI54.6
Support$130.36
Resistance$150.58
MA 20$139.94
MA 50$132.13
MA 200$139.62
MACDBearish
VolumeDecreasing
Fear & Greed Index91.61
Valuation
Fair Value$73.83
Target Price$169.50
Upside/Downside19.50%
GradeOvervalued
TypeGrowth
Dividend Yield1.43%
Risk Assessment
Beta1.40
Volatility41.18%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.